Express $75 million in late-clinical therapies, GSK expands antibiotic pipeline
Time of Update: 2022-10-01
▲If you have any business needs, please long press to scan the QR code above, or▎Editor of WuXi AppTec content teamRecently, GSK and Spero Therapeutics jointly announced that GSK will obtain an exclusive license for the Spero late-stage antibiotic drug tebipenem HBr. This exclusive license will allow GSK to commercialize tebipenem HBrs in all regions except Japan and certain other Asian countries and regions.
A review of the research progress of leukemia stem cells in acute T lymphoblastic leukemia
Time of Update: 2022-06-18
At present, with the continuous emergence of research results on the maintenance and proliferation of LSCs in human and mouse T-ALL models, as well as on the key signaling pathways involved in regulating self-renewal, we review the signaling pathways related to leukemia stem cells in T-ALL, and summarize Summarize the roles of these signaling pathways in leukemia progression .
GSK/Vir neutralizing antibody sotrovimab was granted emergency use authorization by the U.S. FDA
Time of Update: 2021-05-31
(Sina Pharmaceutical News) Reference source: FDA authorizes Vir-GSK antibody as variants threaten Eli Lilly mAb On May 26, the US FDA granted emergency use authorization (EUA) for the COVID-19 monoclonal antibody drug sotrovimab for mild to moderate patients who tested positive for the virus and have a high risk of developing severe COVID-19 (including hospitalization and death) Adults and adolescents (12 years and older, weighing at least 40 kg) patients.
Bringer Ingelheim, a medical fast reading society, gave up Bi 1467335 for NASH indications
Time of Update: 2019-12-19
[December 19, 2019 / list of medical information] the standards for the speciation and valence determination of mercury and arsenic in the new edition of Pharmacopoeia are to be upgraded; Fujifilm acq